![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0020.png)
Biomedical Research
|
Volume 29
Page 58
allied
academies
CARDIOLOGY AND CARDIOVASCULAR MEDICINE
STEM CELLS AND REGENERATIVE MEDICINE
&
International Conference on
International Conference on
J u n e 1 8 - 1 9 , 2 0 1 8 | O s a k a , J a p a n
Joint Event on
STAGE SPECIFIC DIFFERENTIATION OF WHARTON JELLY DERIVED
MESENCHYMAL STEM CELLS TO GENERATE HIGH QUALITY
NEURONS
Zaffar Equbal
National Institute of Immunology, India
N
eurodegenerative disorders of the central nervous system (CNS) remain as one of the major health concern, accounting
for more than 10% of deaths due to different diseases. In neurodegenerative disorders, Alzheimer’s disease, Parkinson’s
disease (PD), Amyotrophic lateral sclerosis (ALS), Multiple system atrophy (MSA) and Huntington disease are the major
contributors. The current therapy, which involves medication and deep brain stimulation at advance stage, focuses on
symptomatic treatment with none of them being able to counteract the progression of the disease. Keeping in mind the
limitations associated with the present treatments, study of cell based therapy has been initiated. In this study we have
successfully trans-differentiated Wharton Jelly derived mesenchymal Stem cells (WJ-MSCs) into neuronal fate. WJ-MSCs
were chosen for the study because of their hypoimmunogenic, immunomodulatory, and non-tumorigenic property. WJ-
MSCs upon treatment with FGF-2 and EGF acquired neuroectodermal fate. Further analysis of these cells confirmed drastic
decrease in the expression of MSCs related genes with concomitant expressing of SOX1, the important transcription factor
involved in neural fate determination. Moreover, there was a drastic reduction in the number of cells expressing CD73 and
CD105, pan-markers of MSCs. These neuroectodermal cells where further induced and differentiated into mature neuronal
cells.
Zaffar.equbal@nii.ac.inBiomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C2-006